What Have We Got to Lose?
作者信息
McNeil Catriona M
机构信息
Catriona M. McNeil, From Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
出版信息
J Clin Oncol. 2016 Dec 20;34(36):4443-4444. doi: 10.1200/JCO.2016.70.8925. Epub 2016 Nov 7.
PMID:27998220
Abstract
摘要
相似文献
1
What Have We Got to Lose?
J Clin Oncol. 2016 Dec 20;34(36):4443-4444. doi: 10.1200/JCO.2016.70.8925. Epub 2016 Nov 7.
2
On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Clin Cancer Res. 2017 Oct 15;23(20):5999-6001. doi: 10.1158/1078-0432.CCR-17-2332.
3
Making precision oncology the standard of care.
Lancet Oncol. 2017 Jul;18(7):835. doi: 10.1016/S1470-2045(17)30474-6.
4
Toxicities of checkpoint inhibitors: causes and management.
Clin Adv Hematol Oncol. 2019 Apr;17(4):220-222.
5
Hyperprogressive disease with anti-PD-1 and anti-PD-L1.
Lancet Oncol. 2016 Dec;17(12):e527. doi: 10.1016/S1470-2045(16)30590-3. Epub 2016 Nov 18.
6
PD1 inhibitors and hair repigmentation: A desirable new side effect.
Dermatol Ther. 2018 Jan;31(1). doi: 10.1111/dth.12560. Epub 2017 Oct 15.
7
Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.
Eur J Cancer. 2018 Nov;104:243-246. doi: 10.1016/j.ejca.2018.09.014. Epub 2018 Oct 25.
8
A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.
Eur J Cancer. 2018 Nov;104:104-107. doi: 10.1016/j.ejca.2018.09.015. Epub 2018 Oct 18.
9
Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment.
Eur J Cancer. 2018 Nov;104:247-249. doi: 10.1016/j.ejca.2018.09.016. Epub 2018 Oct 28.
10
Calling time on the immunotherapy gold rush.
Lancet Oncol. 2017 Aug;18(8):981. doi: 10.1016/S1470-2045(17)30521-1. Epub 2017 Jul 26.
Zotero 插件